Triveram in patients with hypertension and concomitant primary hypercholesterolemia or mixed hyperlipidemia
| ISRCTN | ISRCTN54275632 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN54275632 |
| Protocol serial number | IC4-05153-179-DEU |
| Sponsor | Servier Deutschland GmbH (Germany) |
| Funder | Servier Deutschland GmbH (Germany) |
- Submission date
- 11/04/2016
- Registration date
- 30/06/2016
- Last edited
- 09/02/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Cardiovascular (heart) diseases present are the most frequent reason for premature death, accounting for almost 4 million deaths in Europe per year. High blood pressure (hypertension) and high levels of blood lipids (fats) are two of the most commonly co-occurring cardiovascular risk factors. More than 64% of patients with high blood pressure also have high blood fat levels, and conversely, almost 47% of patients with high blood fat also have high blood pressure. These two factors together cause an accelerated damage to blood vessels. Treatment with a combination of the blood pressure lowering drugs perindopril and amlodipine with a lipid-lowering agent atorvastatin has been found to better protect against cardiovascular events such as heart attacks compared to a similar combination of betablocker, diuretic and atorvastatin. Triveram® is a combination of the above mentioned agents, atorvastatin, perindopril and amlodipine, in a single tablet. It is used to treat high blood pressure and/or stable coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) in adults who also suffer from elevated cholesterol levels (primary hypercholesterolemia) or elevated cholesterol and fat (triglyceride) levels at the same time (combined or mixed hyperlipidemia). Triveram® is intended for patients already on treatment with atorvastatin, perindopril and amlodipine as single tablets. The aim of this study is to gather information on the use of Triveram® in adult outpatients suffering the above mentioned diseases in daily practice, with a focus on changes in blood pressure, lipid parameters and other treatments, as well as treatment adherence, pill burden and treatment satisfaction.
Who can participate?
Adult outpatients with arterial hypertension and elevated cholesterol levels or elevated cholesterol and fat levels at the same time.
What does the study involve?
All patients involved in the study are treated with Triveram® under the circumstance that the decision about the treatment was made before the start of the study. The patients are asked to come to two follow-up visits after 1 and 4 months. During these visits a routine practice investigation is carried out and a form will be filled out by the treating physician regarding blood pressure, blood lipids (fats), and other diseases and medications. The patients are asked to fill out the patient questionnaire about treatment adherence, pill burden and treatment satisfaction at the first and the last visit.
What are the possible benefits and risks of participating?
There are no particular benefits or risks of participating in this study. The treatment given to the patient is the standard medical routine treatment and is completely independent of the study. Patients are free to withdraw from the study at any time without giving a particular reason.
Where is the study run from?
It is planned that the study will be carried out by about 700 general practitioners and cardiologists across Germany. There is no lead center.
When is the study starting and how long is it expected to run for?
April 2016 to May 2017
Who is funding the study?
Servier Deutschland GmbH (Germany)
Who is the main contact?
Dr Bettina Weger
bettina.weger@servier.com
Contact information
Scientific
Servier Deutschland GmbH
Elsenheimerstr. 53
München
80687
Germany
| Phone | +49 (0)89 57095488 |
|---|---|
| bettina.weger@servier.com |
Study information
| Primary study design | Observational |
|---|---|
| Study design | Prospective open multicenter single-arm observational non-interventional study |
| Secondary study design | Longitudinal study |
| Study type | Participant information sheet |
| Scientific title | TRIVERAM-PRACTICE: an open, multi-center, single-arm, non-interventional, observational study in hypertensive outpatients with concomitant primary hypercholesterolemia or mixed hyperlipidemia treated with Triveram in Germany |
| Study acronym | TRIVERAM-PRACTICE |
| Study objectives | In previous clinical studies the free combination of Perindopril, Amlodipine and Atorvastatin showed good efficacy in treatment of patients with essential hypertension and concomitant hypercholesterolemia. Data are lacking on the practical use of a new fixed-dose combination of atorvastatin, perindopril and amlodipine - Triveram® - in daily practice in patients with hypertension and concomitant primary hypercholesterolemia or mixed hyperlipidemia. |
| Ethics approval(s) | Freiburg Ethics Committee International, 29/02/2016, ref: 016/1161 |
| Health condition(s) or problem(s) studied | Essential hypertension with concomitant primary hypercholesterolemia or mixed hyperlipidemia |
| Intervention | This is strictly a non-interventional observational study. Only interventions in line with and not exceeding the standard medical routine are allowed. All patients involved in the study will be treated with Viacoram® under the circumstance that the decision about the treatment was done prior to the study initiation. After the inclusion the patients will be asked to come to two follow-up visits after 1 and 4 months. During these visits a routine practice investigation will be carried out and a case report form regarding blood pressure, lipid parameters, concomitant diseases and co-medications will be filled out by the treating physician. The patients will be asked to fill out the patient questionnaire to therapy adherence, pill burden and therapy satisfaction at the first and the last visit. |
| Intervention type | Other |
| Primary outcome measure(s) |
Office blood pressure and lipid parameters measured within the daily medical routine at inclusion, after approx. 1 month and at study final examination after approx. 4 months. |
| Key secondary outcome measure(s) |
1. Ambulatory blood pressure monitoring only in measured as part of the medical routine at inclusion, after approx. 1 month and at study final examination after approx. 4 months |
| Completion date | 31/05/2017 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 1350 |
| Total final enrolment | 483 |
| Key inclusion criteria | Adult patients with essential hypertension and concomitant hypercholesterolemia or mixed hyperlipidemia eligible for the treatment with Triveram® in line with the marketing authorization for whom the treatment decision was done prior to study inclusion. |
| Key exclusion criteria | N/A |
| Date of first enrolment | 04/04/2016 |
| Date of final enrolment | 31/12/2016 |
Locations
Countries of recruitment
- Germany
Study participating centre
Germany
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Available on request |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Bettina Weger (bettina.weger@servier.com). The data is available upon request from now until 2025. Data will be shared only for scientific purposes in electronic format. Informed consent was obtained from all participants. Individual data are anonymized. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Basic results | 19/01/2021 | No | No | ||
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
09/02/2021: Internal review.
19/01/2021: The following changes were made to the trial record:
1. Contact details, publication and dissemination plan and IPD sharing statement were updated.
2. Total final enrolment added.
